- Home
- » Tags
- » Varenicline
Top View
- A Summary of the Cochrane Review
- Extinction with Varenicline and Nornicotine, but Not ABT-418, Weakens Conditioned Responding Evoked by the Interoceptive Stimulus Effects of Nicotine Carmela M
- Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal
- Title Page Selective Enhancement of Alcohol Aversion by Nicotinic
- The Effects of Varenicline on Working Memory and Long-Term Potentiation in Non-Smokers with Schizophrenia
- Registration, Results Reporting, and Publication Bias of Clinical Trials Supporting FDA Approval of Neuropsychiatric Drugs Befor
- Rollema-Monoamines-Chantix-Rat
- Combination Bupropion SR and Varenicline for Smoking Cessation: a Systematic Review
- Smoking and Crohn's Disease: the Facts
- Nicotine Receptor Partial Agonists for Smoking Cessation (Review)
- Nicotinic Partial Agonists, Varenicline and Sazetidine-A, Have Differential
- Is Varenicline More Effective in Long Term Abstinence from Smoking
- Treatment of Alcohol Use Disorders New Options for Better Outcomes
- Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: a Randomized Controlled Trial
- Apo-Varenicline (Varenicline Tartrate) 0.5 Mg and 1 Mg (Based on Free Base Equivalents) Tablets to Address Drug Shortage
- ACHV SRNT-E Presentation
- Basic and Clinical Pharmacology of Varenicline
- A.38 Varenicline – Smoking Cessation – EML A.5 Bupropion – Smoking Cessation – EML
- Prescription Drugs Associated with Reports of Violence Towards Others
- Mania Induced by Varenicline[Version 1; Peer Review: 1 Approved With
- Varenicline, an Nicotinic Acetylcholine Receptor Partial Agonist, Vs Sustained-Release Bupropion and Placebo for Smoking Cessation
- Pharmacological Interventions for Smoking Cessation: an Overview and Network Meta-Analysis (Review)
- Nicotinic Acetylcholine Receptors in the Human Brain
- That the Ultimate
- An R4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
- Quarterwatch: Data from 2013 Quarters 2 & 3
- New Developments in Tx of Alcohol Dependence: Baclofen and Sodium Oxybate
- VARENICLINE Medication Together with Behavioral Counseling Gives You the Best Chance of Quitting Smoking
- Strong Safety Signal Seen for New Varenicline Risks
- Acute Activation, Desensitization and Smoldering Activation of Human Acetylcholine Receptors
- NDA/BLA Multi-Disciplinary Review and Evaluation
- SUBSTANCE-RELATED DISORDERS Psy23 (1)
- The Nicotinic Acetylcholine Receptor Partial Agonist Varenicline and the Treatment of Drug Dependence: a Review Cleo L
- Shortage of Champix (Varenicline) Film-Coated Tablets, 0.5 Mg, 1 Mg
- The Efficacy and Safety of Varenicline Alone Versus in Combination With
- CHAPTER 2: the Nicotinic Pharmacophore: the Pyridine N of Nicotine and Carbonyl of Ach Hydrogen Bond Across a Subunit Interface to a Backbone NH∗
- Selective and Regulated Trapping of Nicotinic Receptor Weak Base Ligands and 2 Relevance to Smoking Cessation 3 4 5 6 Anitha P
- Effects of Chronic Varenicline Treatment on Nicotine, Cocaine, and Concurrent Nicotine&Plus
- Varenicline Decreases Alcohol Consumption in Heavy-Drinking Smokers
- Drug Interactions with Smoking Cessation Medications and Tobacco Smoke*
- Varenicline Pfizer
- Selective and Regulated Trapping of Nicotinic Receptor Weak
- Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior
- Stereochemical Synthesis of Ring E Analogs of Methyllycaconitine and 4,5-Disubstituted
- Varenicline Rescues Nicotine-Induced Decrease in Motivation for Sucrose Reinforcement
- Journal of Clinical and Diagnostic Research
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2B Trial of Cytisine in Adult Smokers
- Enhancement of Opioid Antinociception by Nicotinic Ligands
- Psychopharmacology After Brain Injury Mel B. Glenn, M.D
- Reference: WLI/100 28 March 2007
- Cytisine for Smoking Cessation: a Research Agenda Jean-Franc¸Ois Etter A,∗, Ronald J
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Varenicline on Cue-Reactivity in Individuals with Concurrent Tobacco Dependence and Heavy Alcohol Use: a Randomized, Double-Blind, Placebo-Controlled Trial
- Paul M. Cinciripini, Ph.D
- New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated and What Is
- Pharmacological and Molecular Studies on the Interaction of Varenicline with Different Nicotinic Acetylcholine Receptor Subtypes
- Preclinical Evaluation of Lobeline for the Treatment of Adhd: Comparison with Psychostimulant Therapies
- Newsletterno1 2013EC.Pdf
- Lobeline Attenuates the Locomotor-Activating Properties of Repeated Morphine Treatment in Rats
- Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys
- Update on Pharmacologic Options for Smoking Cessation Treatment Mitchell Nides, Phd Los Angeles Clinical Trials, Los Angeles, California, USA
- Nicotine Receptor Partial Agonists for Smoking Cessation | COCHRANE HIGHLIGHTS
- Transporter-Mediated Drug-Drug Interactions (Ddis)
- Oral Sazetidine-A, a Selective Α4β2* Nicotinic Receptor Desensitizing Agent, Reduces Nicotine Self-Administration in Rats T
- Summary Charts for Tobacco Cessation Pharmacology Copy
- Varenicline: Risk of Loss of Consciousness
- Patient Safety: Psychosis As the Diagnosis, Drugs As the Cause
- CHANTIX for the Occurrence of Such Symptoms and CHANTIX Safely and Effectively
- Cytisine Versus Varenicline for Smoking Cessation for Māori (The
- Varenicline Bupropion Seizure Risk 11.20.17
- Chantix (Varenicline)
- Psychotropic Medication Side Effects
- An Algorithm for Tailoring Pharmacotherapy for Smoking Cessation: Results from a Delphi Panel of International Experts P Bader,1 P Mcdonald,2 P Selby3